靶向肝细胞癌起始细胞中的免疫逃逸
Targeting immune evasion in hepatocellular carcinoma-initiating cells.
作者信息
Sirera Rafael, Beltrán-Visiedo Manuel, Galluzzi Lorenzo
机构信息
Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA; Department of Biotechnology, Universitat Politècnica de València, Valencia, Spain; Unidad Mixta TRIAL, Centro Investigación Príncipe Felipe-Fundación Investigación, Hospital General Universitario de Valencia, Valencia, Spain; Centro de Investigación Biomédica en Red Cáncer, CIBERONC, Madrid, Spain.
Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA, USA.
出版信息
Trends Immunol. 2025 Jan;46(1):4-6. doi: 10.1016/j.it.2024.12.002. Epub 2024 Dec 24.
Tumor-initiating cells (TICs) are particularly efficient at evading detection and elimination by the human immune system. Recent data from Yang and collaborators demonstrate that - at least in preclinical hepatocellular carcinoma models - the immunological privilege of CD49f TICs can be limited by targeting CD155, resulting in restored sensitivity to immune checkpoint inhibitors.
肿瘤起始细胞（TICs）在逃避免疫系统的检测和清除方面特别有效。杨及其合作者的最新数据表明，至少在临床前肝细胞癌模型中，靶向CD155可限制CD49f TICs的免疫豁免权，从而恢复对免疫检查点抑制剂的敏感性。
Zotero 插件